Pharmaceutical composition with fat reducing effect and application thereof

A composition and action technology, applied in the directions of drug combinations, medical preparations containing active ingredients, pharmaceutical formulations, etc., to achieve the effects of avoiding side effects, suppressing adverse reactions, and low laser power

Active Publication Date: 2021-01-15
XIAMEN UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the combination drug of photosensitizer plus rosiglitazone that can be used for weight loss has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition with fat reducing effect and application thereof
  • Pharmaceutical composition with fat reducing effect and application thereof
  • Pharmaceutical composition with fat reducing effect and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Effects of photosensitizer-rosiglitazone composition on killing mature adipocytes and reducing fat under light

[0029] a.Experimental method

[0030] First, by chemical induction method, that is, co-incubating with 0.5mmol / L 3-isobutyl-1-methylxanthine + 1μmol / L dexamethasone + 10μg / mL insulin for 2 days, and then continuing with 10μg / mL insulin 3T3-L1 embryonic fibroblasts were induced into mature adipocytes by incubation for more than 8 days.

[0031] These cells were then divided into 4 groups and incubated separately as follows:

[0032] a) Control group: DMEM medium containing PBS;

[0033] b) zinc phthalocyanine group: DMEM medium containing 20 μg zinc phthalocyanine per milliliter;

[0034] c) Rosiglitazone group: DMEM medium containing 2 μg rosiglitazone per milliliter;

[0035] d) Zinc phthalocyanine+rosiglitazone group: DMEM medium containing 22 μg zinc phthalocyanine-rosiglitazone composition (mass ratio of the two components: 10:1) per milliliter.

[0...

Embodiment 2

[0052] Fat reduction effect of photosensitizer-rosiglitazone composition on obese mice under light

[0053] a.Experimental method

[0054] First, 24 healthy male ob / ob mice (purchased from the Experimental Animal Center of Xiamen University) aged about 16 weeks were taken, fed with standard mouse growth feed for 2 weeks in a conventional experimental environment, and then randomly divided into 4 groups. In each group, the mice in each group were given drugs by tail vein injection, and the specific grouping administration situation was as follows:

[0055] a) Control group: normal saline

[0056] b) Zinc phthalocyanine group: 12mg / kg zinc phthalocyanine

[0057] c) Rosiglitazone group: 3mg / kg rosiglitazone

[0058] d) Zinc phthalocyanine + rosiglitazone group: Zinc phthalocyanine-rosiglitazone composition (12 mg / kg: 3 mg / kg)

[0059] About 1 hour after injection, use a 630nm laser (power 0.05W / cm 2 ) to continuously irradiate the mouse abdomen for 30 minutes.

[0060] One...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of weight reducing medicines, and provides a pharmaceutical composition with a fat reducing effect. The pharmaceutical composition with the fat reducing effect comprises a photosensitizer and rosiglitazone; the photosensitizer comprises one or a mixture of more of photoporphyrin, viltipofen, temopofen, chlorin e6, zinc phthalocyanine and 5-aminolevulinic acid; and the mass ratio of the photosensitizer to the rosiglitazone is 3: 1-10: 1. When the pharmaceutical composition is applied, the pharmaceutical composition powder is diluted and dissolved bynormal saline, and then the pharmaceutical composition is administrated in an intravenous injection mode. Photodynamic cell killing of the photosensitizer is combined with cell browning induction of the rosiglitazone, so that an optimal weight losing strategy combining 'fast and slow ' and 'local and integrity' is realized. The two drug effects are good complementary pairs, and experimental results show that the two drug effects have quite good synergistic effects. In addition, the rosiglitazone also has an obvious inhibition effect on adverse reactions possibly caused by photosensitizer treatment.

Description

technical field [0001] The present invention generally relates to the technical field of weight-loss drugs, in particular to a pharmaceutical composition with fat-reducing effect and application thereof. Background technique [0002] Obesity is a public health problem that seriously endangers the health of the population. Currently, more than one-third of adults (over 18 years old) are obese or overweight worldwide. The danger of obesity is that it is a risk factor for various diseases, such as cardiovascular and cerebrovascular diseases, diabetes, fatty liver, tumors and so on. Conventional treatment for obesity: intervene in living habits, restrict food intake, increase energy consumption, etc.; take weight-loss drugs, suppress appetite or reduce the absorption of lipids in intestinal chyme, etc.; implement weight-loss surgery to reduce gastric Capacity, to speed up gastric emptying, etc. Although there are many methods, but affected by various factors, the final weight...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K41/00A61K31/4439A61P3/04
CPCA61K31/4439A61K41/0061A61K41/0071A61P3/04A61K2300/00
Inventor 聂立铭陈荣河任磊
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products